- Home
- PLX vs ALEC Comparison
PLX vs ALEC Comparison
Compare PLX & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- ALEC
- Stock Information
- Founded
- PLX 1993
- ALEC 2013
- Country
- PLX United States
- ALEC United States
- Employees
- PLX N/A
- ALEC N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- ALEC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PLX Health Care
- ALEC Health Care
- Exchange
- PLX Nasdaq
- ALEC Nasdaq
- Market Cap
- PLX 122.6M
- ALEC 124.0M
- IPO Year
- PLX 1998
- ALEC 2019
- Fundamental
- Price
- PLX $1.37
- ALEC $1.55
- Analyst Decision
- PLX Strong Buy
- ALEC Buy
- Analyst Count
- PLX 1
- ALEC 7
- Target Price
- PLX $15.00
- ALEC $4.70
- AVG Volume (30 Days)
- PLX 1.3M
- ALEC 537.2K
- Earning Date
- PLX 08-13-2025
- ALEC 08-06-2025
- Dividend Yield
- PLX N/A
- ALEC N/A
- EPS Growth
- PLX N/A
- ALEC N/A
- EPS
- PLX 0.05
- ALEC N/A
- Revenue
- PLX $59,764,000.00
- ALEC $88,339,000.00
- Revenue This Year
- PLX $65.02
- ALEC N/A
- Revenue Next Year
- PLX $57.34
- ALEC $319.82
- P/E Ratio
- PLX $28.34
- ALEC N/A
- Revenue Growth
- PLX 0.18
- ALEC N/A
- 52 Week Low
- PLX $0.82
- ALEC $0.87
- 52 Week High
- PLX $3.10
- ALEC $6.78
- Technical
- Relative Strength Index (RSI)
- PLX 41.78
- ALEC 52.60
- Support Level
- PLX $1.43
- ALEC $1.41
- Resistance Level
- PLX $1.54
- ALEC $1.75
- Average True Range (ATR)
- PLX 0.09
- ALEC 0.12
- MACD
- PLX 0.01
- ALEC 0.01
- Stochastic Oscillator
- PLX 5.77
- ALEC 51.85
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.